Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer

In the era of value-based oncology care, stakeholders are increasingly using patient reported outcomes (PROs) to guide clinical and regulatory decisions. PROs are also included in health technology assessments to guide patient access, drug reimbursement and pricing. We reviewed PROs collected in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaim, Remziye, Redekop, Ken, Uyl-de Groot, Carin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034386/
https://www.ncbi.nlm.nih.gov/pubmed/35429903
http://dx.doi.org/10.1016/j.tranon.2022.101418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034386/
https://www.ncbi.nlm.nih.gov/pubmed/35429903
http://dx.doi.org/10.1016/j.tranon.2022.101418

Ejemplares similares